Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I | Q9P0X4 | 4/20 | 0.76 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.74 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.74 |
| ▸ | CNR2 | P34972 | 4/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | IDH1 | O75874 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 3/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8053828 | 0.87 | CACNA1I (0.57) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL2901146 | 0.87 | CACNA1I (1.00) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL23327963 | 0.85 | CACNA1I (1.00) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL8233861 | 0.85 | CACNA1I (1.00) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL29363972 | 0.85 | CACNA1I (1.00) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL1063200 | 0.82 | CACNA1I (0.75) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL3053738 | 0.81 | CACNA1I (0.74) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL1060457 | 0.80 | CACNA1I (0.82) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL20328496 | 0.80 | CACNA1I (0.86) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| Suvecaltamide SCHEMBL21828396 | 0.79 | CACNA1I (1.00) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212291-B1 | HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-06-04 | — | — | EP | claimed |
| US-8637513-B2 | Heterocycle phenyl amide T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-01-28 | — | — | US | claimed |
| US-20100261724-A1 | HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-10-14 | — | — | US | claimed |
| EP-2212291-A1 | HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2010-08-04 | — | — | EP | claimed |
| WO-2009054984-A1 | HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2009-04-30 | — | — | WO | claimed |
| EP-2212291-B1 | HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-06-04 | — | — | EP | disclosed |
| EP-2212291-B1 | HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-06-04 | — | — | EP | disclosed |
| US-8637513-B2 | Heterocycle phenyl amide T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637513-B2 | Heterocycle phenyl amide T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637513-B2 | Heterocycle phenyl amide T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20100261724-A1 | HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-10-14 | — | — | US | disclosed |
| US-20100261724-A1 | HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-10-14 | — | — | US | disclosed |
| US-20100261724-A1 | HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-10-14 | — | — | US | disclosed |
| WO-2009054984-A1 | HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261724-A1 | HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | CACNA1G, CACNA1H, CACNA1I | CACNA1I 3/4885CACNA1G 1/4885CACNA1H 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.